Get the Stockscreener App
559.53
1.54%
-8.73
Pre-market:
560.13
0.60
+0.11%
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $559.53, with a volume of 1.96M.
It is down -1.54% in the last 24 hours and up +9.06% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
See More
Previous Close:
$568.26
Open:
$565
24h Volume:
1.96M
Relative Volume:
0.83
Market Cap:
$207.93B
Revenue:
$45.20B
Net Income/Loss:
$6.87B
P/E Ratio:
30.76
EPS:
18.1888
Net Cash Flow:
$6.75B
1W Performance:
+6.33%
1M Performance:
+9.06%
6M Performance:
-10.32%
1Y Performance:
+16.98%
1-Day Range:
$556.01
$568.35
1-Week Range:
$495.04
$587.49
52-Week Range:
$435.27
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
559.53 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.50 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
556.20 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
137.89 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
258.03 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | DZ Bank | Buy |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-08-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Dec-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-11-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-19-25 | Initiated | William Blair | Outperform |
| Jul-24-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jul-09-25 | Downgrade | UBS | Buy → Neutral |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Form 144 THERMO FISHER SCIENTIFIC INC. For: 27 July By Investing.com - Investing.com India
Daily Brief Health Care: Apnimed, Chugai Pharmaceutical, Equifax Inc, Royalty Pharma , Startline, Surgery Partners, Teva Pharmaceutical Sp Adr, Thermo Fisher Scientific Inc and more - Smartkarma
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
TMO Maintained by Piper Sandler -- Price Target Raised to $600 - GuruFocus
Thermo Fisher (TMO) insider files to sell 400 common shares valued at $226,000 - Stock Titan
Piper Sandler Adjusts Price Target on Thermo Fisher Scientific to $600 From $510, Maintains Neutral Rating - marketscreener.com
Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026 - Yahoo Finance
Thermo Fisher stock holds on steady earnings base - Ad-hoc-news.de
THERMO FISHER SCIENTIFIC INC : PIPER SANDLER RAISES TARGET PRICE TO $600 FROM $510 - Bitget
Thermo Fisher Scientific (NYSE:TMO) Faces A Margin Test - Kalkine Media
Thermo Fisher Scientific Q2 up 10% to USD 11.99 billion - Medical Buyer
Thermo Fisher stock trades steadily as diagnostics and biopharma demand support earnings trajectory - AD HOC NEWS
Thermo Fisher Scientific Inc. (TMO) Leads with RSI of 73 Amid Ea - GuruFocus
Thermo Fisher Scientific Inc. (TMO) stock price, news, quote and history - Yahoo Finance Singapore
Thermo Fisher Scientific Inc. Revenue Breakdown – BX:TN8 - TradingView
Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools BetsDanaher (NY - Benzinga
Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing - 01net
Thermo Fisher posts strong Q2 2026 with 10% rev... - Pluang
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider - GlobeNewswire Inc.
Company News for July 24, 2026 - Yahoo Finance
Deutsche Bank Adjusts Thermo Fisher Scientific Price Target to $635 From $630, Maintains Buy Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Thermo Fisher Scientific to $660 From $615, Maintains Overweight Rating - marketscreener.com
Rothschild & Co Redburn Raises Price Target on Thermo Fisher Scientific to $625 From $610, Maintains Buy Rating - marketscreener.com
Thermo Fisher Raised Full-Year Guidance After a Standout Q2 Earnings Call - TIKR.com
RBC Raises Price Target on Thermo Fisher Scientific to $580 From $490, Keeps Sector Perform Rating - marketscreener.com
Barclays Adjusts Thermo Fisher Scientific Price Target to $650 From $625, Maintains Overweight Rating - marketscreener.com
Thermo Fisher raises 2026 outlook after 10% growth in Q2 - Yahoo Finance
Bernstein Adjusts PT on Thermo Fisher Scientific to $575 From $520, Maintains Market Perform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Thermo Fisher Scientific to $650 From $570, Maintains Buy Rating - marketscreener.com
Thermo Fisher (TMO) Lands ImmuPharma Kapiglucagon Diabetes Manufacturing Role - Yahoo Finance
Thermo Fisher stock holds steady ahead of earnings - Ad-hoc-news.de
THERMO FISHER SCIENTIFIC INC : LEERINK PARTNERS RAISES TARGET PRICE TO $620 FROM $600 - Bitget
Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades - Yahoo! Finance Canada
Thermo Fisher Scientific Q2 Earnings Call Highlights - Yahoo Finance
TMO Q2 FY2026 earnings call - finance.biggo.com
Is It Too Late to Buy Thermo Fisher Scientific Inc (TMO) After 8 - GuruFocus
THERMO FISHER SCIENTIFIC INC : EVERCORE ISI RAISES TARGET PRICE TO $615 FROM $570 - Bitget
Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $606.79, Implies 15% Upside - TradingView
Jefferies Adjusts Price Target on Thermo Fisher Scientific to $630 From $585, Maintains Buy Rating - Moomoo
Thermo Fisher Scientific Inc.'s stock price skyrockets to $572.32, marking an impressive 8.71% surge - Smartkarma
Thermo Fisher Stock Jumps on Second Quarter Results - WFMZ.com
Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlig - GuruFocus
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market - MarketWatch
Thermo Fisher Scientific (TMO) Reports Strong Q2 2026 Earnings a - GuruFocus
Thermo Fisher Scientific Inc Stock Price Live, Charts & News - The Economic Times
Thermo Fisher Points to Improving End-Market ActivityThermo Fisher Scientific (NYSE:TMO) - Benzinga
Leerink Partners Adjusts Price Target on Thermo Fisher to $620 From $600, Maintains Outperform Rating - marketscreener.com
Thermo Fisher TMO Stock Draws Bullish Calls Ahead Of Q2 - timothysykes.com
Thermo Fisher Scientific Reports Second Quarter 2026 Results - BioSpace
Thermo Fisher Scientific (NYSE:TMO) Gains Focus In A Selective Market - Kalkine Media
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.61%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):